相关实验视频

Updated: Jul 24, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

一个TFEB-扩大细胞癌与长期,完整的免疫疗法反应:回顾性支持分子分类的价值

Steven Christopher Smith¹, Jinxing Yu², Asit K Paul³

¹Departments of Pathology and Surgery, VCU School of Medicine, Massey Comprehensive Cancer Center, and Richmond Veterans Affairs Medical Center, Richmond, VA, USA.

International journal of surgical pathology

|July 7, 2023

概括

一种罕见的癌亚型,TFEB增强细胞癌 (RCC),对PD-L1免疫疗法显示出完全的反应. 这表明免疫疗法可能是这种分子定义癌症的可行治疗方法.

科学领域:

在瘤学瘤学.
分子病理学分子病理学
免疫治疗是一种免疫疗法.

背景情况:

世界卫生组织 (WHO) 现在分类细胞癌 (RCC) 亚型,包括分子定义的类别.
增强TFEB的RCC是一种分子定义的亚型,具有潜在的治疗意义.
在TFEB增强的RCC中频繁的PD-L1表达表明对免疫治疗的潜在敏感性.

研究的目的:

报告一个转移性TFEB增强RCC的病例.
为了研究PD-L1导向治疗在这种特定的RCC亚型中的疗效.
突出免疫疗法作为TFEB增强RCC的潜在治疗策略.

主要方法:

一位患有转移性TFEB增强RCC的患者的病例报告.
对患者的治疗史和对PD-L1导向治疗的反应进行审查.
与治疗结果相关的PD-L1表达的分析.

主要成果:

患者实现了PD-L1导向治疗的长期,完整的反应.
该疗法最初是在TFEB放大完全特征化之前,在广泛的适用症下进行的.
这一结果支持了在TFEB增强的RCC中免疫治疗疗效的假设.

结论:

TFEB增强的RCC可能对PD-L1定向免疫疗法有反应.
需要进一步的临床研究,以探索针对这种癌分子亚型的免疫疗法.
分子定义的RCC亚型可能受益于有针对性的治疗策略.

关键词:

在 PDL1 中,PDL1 是 PDL1.用TFEB放大细胞癌的瘤.细胞癌的分类细胞癌的分类

更多相关视频

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...